Echosens and Boehringer Ingelheim have expanded their collaboration aimed at expediting progress in metabolic ...

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there ...

Reduced doses in antifibrotic therapy for patients with idiopathic pulmonary fibrosis did not significantly impact outcomes, ...

This expansion will change the trajectory of MASH by focusing on early detection, diagnosis, and access to care.

A novel canine-specific detection algorithm is designed to improve early identification of heart disease and expand access to ...

By combining their diagnostic and therapeutic expertise, Echosens and Boehringer Ingelheim aim to help close persistent gaps ...

Ingelheim: Boehringer Ingelheim and Eko Health have entered a strategic collaboration agreement to improve heart murmur ...

Efimosfermin is a long-acting engineered variant of FGF21 designed to have a prolonged half-life, the authors noted, and has ...

In a pharmaphorum podcast recorded onsite at the Congress, web editor Nicole Raleigh spoke with Itziar Canamasas, global head ...

Korea's Beringer Ingelheim recently held an event for executives and employees '60 seconds to show kidney health' As part of ...

Targeting PDE4 drives anti-inflammatory and antifibrotic effects, and Boehringer has been working on its own PDE4 inhibitor ...

Boehringer Ingelheim & Eko Health ink digital health collaboration to improve heart murmur detection in dogs: Ingelheim, Germany Wednesday, June 11, 2025, 10:00 Hrs [IST] Boehring ...